THURSDAY, Aug. 18, 2016 (HealthDay News)-- Diagnoses of
early prostate cancer continue to decline in the United States, following the U.S. Preventive Services Task Force recommendation against routine screening for the disease, researchers report.
Not exact matches
NEW YORK (360Dx)-- Biotech firm Berg
continued its push into
cancer diagnostics with the presentation of several posters earlier this month at the annual meeting of the American Association for Cancer Research and the preparation of a forthcoming publication detailing an assay for distinguishing between prostate cancer and benign prostate hyperp
cancer diagnostics with the presentation of several posters
earlier this month at the annual meeting of the American Association for
Cancer Research and the preparation of a forthcoming publication detailing an assay for distinguishing between prostate cancer and benign prostate hyperp
Cancer Research and the preparation of a forthcoming publication detailing an assay for distinguishing between
prostate cancer and benign prostate hyperp
cancer and benign
prostate hyperplasia.
Although most agencies providing recommendations on
prostate cancer screening, especially those outside the United States, do not recommend routine PSA testing for the
early detection of
prostate cancer, it
continues to be performed frequently medical experts noted.
PSA testing has been recommended for the
early detection of
prostate cancer for many years; however this new data suggests a baseline PSA could determine who should and should not
continue to be screened for
prostate cancer.